Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives bearing 1H-pyrazole or 1H-1,2,4-triazole by Tarikoğulları, Ayşe H. et al.
Marmara Pharmaceutical Journal 20: 21-27, 2016
DOI: 10.12991/mpj.2016202105828
ORIGINAL ARTICLE
21
Synthesis and cholinesterase inhibitory activity of some phenylacetamide 
derivatives bearing 1H-pyrazole or 1H-1,2,4-triazole
Ayşe H. Tarikoğulları, M. Murat Çizmecioğlu, Merve Saylam,
Sülünay Parlar, Vildan Alptüzün, Zeynep Soyer
Department of Pharmaceutical Chemistry, Faculty of Pharmacy,
Ege University, Bornova, Izmir 35100, Turkey
Corresponding author:
Ayşe H. Tarikoğulları
Department of Pharmaceutical Chemistry 
Faculty of Pharmacy, Ege University, Bornova, Izmir 35100, Turkey
Phone: +90 532 317 34 12
Telefax: +90 232 388 52 58
E-mail: ayse.tarikogullari@ege.edu.tr
Ayşe H. TArikoğullArı, M. Murat ÇiZMecioğlu, Merve SAylAM, Sülünay PArlAr, Vildan AlPTüZün,  
Zeynep Soyer
ABSTRACT
A group of N-phenylacetamide derivatives bearing five 
membered heterocyclic rings, pyrazole or 1,2,4-triazole, 
were synthesized to investigate their cholinesterase 
inhibitory activities. Acetylcholinesterase (Ache) and 
butyrylcholinesterase (Buche) inhibitory activities were 
evaluated by using ellman’s spectroscopic method. results 
indicated that all of the compounds displayed moderate and 
selective Ache inhibitory activity and the most active compound 
was 2-(1H-1,2,4-triazole-1-yl)-N-(3-methoxyphenyl)acetamide 
with an ıc50 value of 6.68 mM. Docking studies were also carried 
out for the most active compound.
Keywords: Alzheimer’s disease, pyrazole, 1,2,4-triazole, 
acetamide, cholinesterase inhibitory activity
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of 
dementia in the elderly. ıt is characterized by irreversible 
degeneration of the cholinergic neurons in the brain, 
accompanied with progressive loss of memory and cognitive 
skills (1, 2). As much of the functional deficit in AD has been 
associated with morphological and functional imbalance 
of the central cholinergic system, choline levels play an 
important role in the treatment of AD (3). According to the 
cholinergic hypothesis, the cognitive and memory symptoms 
of AD are caused by the diminution of acetylcholine, therefore 
the most common strategy is to increase acetylcholine (Ach) 
level by inhibiting acetylcholinesterase (Ache) enzyme (4). 
currently, the therapeutic approach reflecting this hypothesis 
is the treatment with FDA approved drugs like donepezil, 
rivastigmine and galanthamine as Ache inhibitors (1).
Heterocyclic compounds are potentially important nuclei 
for drug discovery as they can interact with molecular 
targets with various binding interaction possibilities. 
Donepezil, rivastigmine and galanthamine also carry 
heterocyclic rings and according to literature survey, most 
of the compounds that have exhibited Ache inhibition 
consists of heterocyclic ring systems including pyrazole 
and 1,2,4-triazole (5-14). Besides Ache inhibitory activity, 
pyrazole and 1,2,4-triazole containing systems have a wide 
Tarikoğullari et al.
Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivatives Marmara Pharm J 20: 21-27, 201622
spectrum of biological activities such as antibacterial, 
antifungal, analgesic, antipyretic, antiinflammatory, 
antiviral, anticancer, antituberculosis, antiparasitic, 
antihyperglycemic, antidepression, antihypertensive, 
vasodilatory, anticonvulsant activity (5, 9, 10, 14-16). 
Ache enzyme structure is a deep and narrow gorge 
approximately 20 Å long consisting of 2 binding sites, 
peripheral anionic site (PAS) and catalytic active site (cAS). 
The PAS is the entrance of the enzyme gorge whereas the 
cAS is the bottom of the gorge (17). The PAS of the Ache 
gorge (for Ache in Torpedo californica - TcAche) includes 
Tyr70, Asp72, Tyr121, Glu278, Trp279 and Tyr334 residues 
that are important for binding interactions of the inhibitors. 
ın the middle of the TcAche gorge, Trp84, Tyr130, Glu199, 
Phe330 and Tyr442 are also five important amino acid 
residues constituting the anionic binding site (18). Molecular 
modeling studies indicated that Ache inhibitors bearing 
heterocyclic rings interact with specific amino acids of either/
both cAS and PAS site of Ache (18, 19). Besides, the narrow 
conformation of the enzyme gorge leads small molecules like 
tacrine and donepezil to fit into the active site easily (1). 
ın the light of these findings, we designed a group of 
N-phenylacetamide derivatives bearing pyrazole and 
1,2,4-triazole to test their cholinesterase inhibitory activity. 
We also evaluated the contribution of the substituents on 
N-phenyl ring to Ache inhibitory activity.
MATERIALS AND METHODS
Chemistry
Analytical thin-layer chromatography (Tlc) was run on 
Merck silica gel plates (kieselgel 60F254) with detection 
by uV light (254 nm). Melting points were determined on 
Stuart SMP30 melting point apparatus and are uncorrected. 
The ır spectra of compounds were recorded as potassium 
bromide pellets on Perkin elmer FT-ır Spectrometer 100 
(Perkin elmer ınc., Massachusetts, uSA). The nMr spectra 
of compounds were recorded on a Varian As 400 Mercury 
Plus nMr (Varian ınc., Palo Alto, cA, uSA) spectrometer. 
HrMS was recorded on a HPlc-ToF Waters Micromass 
lcT Premier Xe (Milford, MA, uSA) mass spectrometer 
using eSı. All starting materials and reagents were high-
grade commercial products.
The title compounds were synthesized in two steps. First, 
substituted anilines and 2-chloroacetyl chloride were 
reacted to obtain 2-chloroanilides according to the reported 
procedure (20), then they were condensed with pyrazole or 
1,2,4-triazole to furnish the title compounds (Scheme 1).
Scheme 1. The synthetic pathway of the title compounds
General procedure for the synthesis of the intermediates
Substituted anilines (0.066 mol, 1.0 equiv.) were dissolved in 
glacial acetic acid (25 ml). 2-chloroacetyl chloride (0.074, 
1.12 equiv.) was added by a seperatory funnel drop wise in 
an ice bath. After the reaction mixture was stirred for 15 
minutes in ice bath then at room temperature for 45 minutes, 
the reaction mixture was poured into saturated sodium 
acetate solution and the precipitate was filtered and washed 
with water. The crude product was dried and crystallized 
from ethanol:water mixture (20).
General procedure for the synthesis of the compounds 
1-12
2-chloro-N-phenylacetamides (1.0 equiv.) and pyrazole or 
1,2,4-triazole (5.0 equiv.) were refluxed in toluene (8-10 ml). 
After confirming the end of the reaction by Tlc, the solvent 
was evaporated. The residue was dissolved in chloroform 
(30 ml) and extracted with water (2x10ml). The organic 
phases were combined and dried over anhydrous na2So4 
and evaporated under reduced pressure. The product was 
purified by crystallization from water (15). The synthetic 
pathway is given in Scheme 1.
N-(2-chlorophenyl)-2-(1H-pyrazol-1-yl)acetamide (1)
Yield 67 %; mp: 105 oC (water) (lit21: mp: 110 oC); IR (KBr) 
υ
max
 (cm-1): 3267 (NH st), 1677 (amide I), 1546 (amide II); 
1H NMR (DMSO-d
6
) υ8.69 (brs, NH), υ8.34 (dd, J: 1.5, 8.2 
Hz, 1H, PhH), υ7.74 (d, J: 2.0 Hz, 1H, PyH), υ7.55 (d, J: 2.4 
Hz, 1H, PyH), υ7.31 (dd, J: 1.3, 7.9 Hz, 1H, PhH), υ7.24 (m, 
1H, PhH), υ7.03 (td, J: 1.5, 7.6 Hz, 1H, PhH), υ6.41 (t, J: 2.2 
Hz, 1H, PyH), υ4.99 (s, 2H, CH
2
) ppm.; HR-MS (EI+), m/z: 
236.0600 (M+, C
11
H
11
N
3
OCl for 236.0591).  
N-(3-chlorophenyl)-2-(1H-pyrazol-1-yl)acetamide (2)
Yield 88 %; mp: 80 oC (water) (lit21: mp: 62 oC); IR (KBr) 
υ
max
 (cm-1): 3325 (NH st), 1676 (amide I), 1549 (amide II); 1H 
NMR (CDCl
3
) υ8.64 (brs, NH), υ7.71 (d, J: 1.6 Hz, 1H, PyH), 
υ7.56 (t, J: 2.0 Hz, 1H, PhH), υ7.53 (d, J: 2.3 Hz, 1H, PyH), 
υ7.30 (m, 1H, PhH), υ7.21 (t, J: 7.5 Hz, 1H, PhH), υ7.07 (m, 
1H, PhH), υ6.39 (t, J: 2.2 Hz, 1H, PyH), υ4.93 (s, 2H, CH
2
) 
Tarikoğullari et al.
Synthesis and cholinesterase inhibitory activity of some phenylacetamide derivativesMarmara Pharm J 20: 21-27, 2016 23
ppm.; HR-MS (EI+), m/z: 236.0597 (M+, C
11
H
11
N
3
OCl for 
236.0591).
N-(4-chlorophenyl)-2-(1H-pyrazol-1-yl)acetamide (3)
Yield 70 %; mp: 175 oC (water); IR (KBr) υ
max
 (cm-1): 3274 
(NH st), 1698 (amide I), 1551 (amide II); 1H NMR (CDCl
3
) 
υ8.58 (brs, NH), υ7.71 (d, J: 1.9 Hz, 1H, PyH), υ7.53 (d, J: 2.3 
Hz, 1H, PyH), υ7.40 (dd, J: 2.2, 6.9 Hz, 2H, Ph2H), υ7.25 (m, 
2H, Ph2H), υ6.39 (t, J: 2.2 Hz, 1H, PyH), 4.93 (s, 2H, CH
2
) 
ppm.; HR-MS (EI+), m/z: 236.0598 (M+, C
11
H
11
N
3
OCl for 
236.0591).
N-(2-methoxyphenyl)-2-(1H-pyrazol-1-yl)acetamide (4)
Yield 57 %; mp: 64 oC (water); IR (KBr) υ
max
 (cm-1): 3270 
(NH-st), 1668 (amide I), 1542 (amide II); 1H NMR (CDCl
3
) 
υ8.54 (brs, NH), υ8.30 (dd, J: 1.6, 8.0 Hz, 1H, PhH), υ7.71 (d, 
J: 1.8 Hz, 1H, PyH), υ7.54 (d, J: 2.3 Hz, 1H, PyH), υ7.02 (td, 
J: 1.6, 7.8 Hz, 1H, PhH), υ6.94 (td, J: 1.2, 7.5 Hz, 1H, PhH), 
υ6.82 (dd, J: 1.2, 8.1 Hz, 1H, PhH), υ6.40 (t, J: 2.2 Hz, 1H, 
PyH), υ4.97 (s, 2H, CH
2
), υ3.78 (s, 3H, OCH
3
) ppm.; HR-MS 
(EI+), m/z: 232.1087 (M+, C
12
H
14
N
3
O
2
 for 232.1086). 
N-(3-methoxyphenyl)-2-(1H-pyrazol-1-yl)acetamide (5)
Yield 65 %; mp: 70 oC (water); IR (KBr) υ
max
 (cm-1): 3271 
(NH-st), 1691 (amide I), 1562 (amide II), 1H NMR (CDCl
3
) 
υ8.20 (brs, NH), υ7.70 (d, J: 2.0 Hz, 1H, PyH), υ7.53 (d, J: 
2.4 Hz, 1H, PyH), υ7.17 (m, 2H, Ph2H), υ6.90 (dd, J: 1.8, 8.1 
Hz, 1H, PhH), υ6.66 (dd, J: 2.4, 8.2 Hz, 1H, PhH), υ6.38 (t, 
J: 2.0 Hz, 1H, PyH), υ4.93 (s, 2H, CH
2
), υ3.78 (s, 3H, OCH
3
) 
ppm.; HR-MS (EI+), m/z: 232.1089 (M+, C
12
H
14
N
3
O
2
 for 
232.1086);   
N-(4-methoxyphenyl)-2-(1H-pyrazol-1-yl)acetamide (6)
Yield 60 %; mp: 133 oC (water); IR (KBr) υ
max
 (cm-1): 3324 
(NH-st), 1682 (amide I), 1555 (amide II); 1H NMR (CDCl
3
) 
υ8.12 (brs, NH), υ7.69 (d, J: 2.0 Hz, 1H, PyH), υ7.53 (d, J: 2.3 
Hz, 1H, PyH), υ7.34 (dd, J: 2.2, 7.0 Hz, 2H, Ph2H), υ6.83 (dd, 
J: 2.2, 7.0 Hz, 2H, Ph2H), υ6.38 (t, J: 2.2 Hz, 1H, PyH), υ4.93 
(s, 2H, CH
2
), υ3.77 (s, 3H, OCH
3
) ppm.; HR-MS (EI+), m/z: 
232.1081 (M+, C
12
H
14
N
3
O
2
 for 232.1086).
N-(2-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide (7)
Yield 27 %; mp: 131 oC (water); IR (KBr) υ
max
 (cm-1): 
3255 (NH-st), 1674 (amide I), 1552(amide II); 1H NMR 
(DMSO-d
6
) υ9.93 (brs, NH), υ8.53 (s, 1H, TrH), υ7.98 (s, 1H, 
TrH), υ7.72 (d, J: 8.2 Hz, 1H, PhH), υ7.50 (d, J: 8.2 Hz, 1H, 
PhH), υ7.32 (t, J: 7.7 Hz, 1H, PhH), υ7.20 (t, J: 7.9 Hz, 1H, 
PhH), υ5.23 (s, 2H, CH
2
) ppm.; HR-MS (EI+), m/z: 237.0542 
(M+, C
10
H
10
N
4
OCl for 237.0543).  
N-(3-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide (8)
Yield 35 %; mp: 157 oC (water); IR (KBr) υ
max
 (cm-1): 
3260 (NH-st), 1705 (amide I), 1550 (amide II); 1H NMR 
(DMSO-d
6
) υ10.56  (brs, NH), υ8.53 (s, 1H, TrH), υ7.97 (s, 
1H, TrH),  υ7.74 (t, J: 2.2 Hz, 1H, PhH), υ7.42 (m, 1H, PhH), 
υ7.34 (t, J: 8.2 Hz, 1H, PhH), υ7.12 (m, J: 7.4 Hz, 1H, PhH), 
υ5.13 (s, 2H, CH
2
) ppm.; HR-MS (EI+), m/z: 237.0547 (M+, 
C
10
H
10
N
4
OCl for 237.0543).
N-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide (9)
Yield 30 %; mp: 205 oC (water); IR (KBr) υ
max
 (cm-1): 
3264 (NH-st), 1704 (amide I), 1557 (amide II); 1H NMR 
(DMSO-d
6
) υ10.48 (brs, NH), υ8.45 (s, 2H, Tr2H),  υ7.58 (d, J: 
9.0 Hz, 2H, Ph-H), υ7.36 (d, J: 8.6 Hz, 2H, PhH), υ5.00 (s, 2H, 
CH
2
) ppm.; HR-MS (EI+), m/z: 237.0548 (M+, C
10
H
10
N
4
OCl 
for 237.0543).
N-(2-methoxyphenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide 
(10)
Yield 17 %; mp: 176 oC (water); IR (KBr) υ
max
 (cm-1): 
3269 (NH-st), 1708 (amide I), 1556 (amide II); 1H NMR 
(DMSO-d
6
) υ10.37 (brs, NH), υ8.54 (s, 1H, TrH), υ7.99 (s, 
1H,, TrH), υ7.26 (s, 1H, PhH), υ7.21 (t, J: 8.1 Hz, 1H, PhH), 
υ7.08 (d, J: 7.6 Hz, 1H, PhH), υ6.67 (dd, J: 2.2, 8.1 Hz, 1H, 
PhH), υ5.12 (s, 2H, CH
2
), υ4.01 (s, 3H, OCH
3
) ppm.; HR-MS 
(EI+), m/z: 233.1046 (M+, C
11
H
13
N
4
O
2
 for 233.1039).
N-(3-methoxyphenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide 
(11)
Yield 56 %; mp: 176 oC (water); IR (KBr) υ
max
 (cm-1): 
3269 (NH-st), 1707 (amide I), 1557 (amide II); 1H NMR 
(DMSO-d
6
) υ10.34 (brs, NH), υ8.52 (s, 1H, TrH), υ7.97 (s, 
1H, TrH), υ7.25 (s, 1H, PhH), υ7.21 (t, J: 8.1 Hz, 1H, PhH), 
υ7.08 (d, J: 8.0 Hz, 1H,  PhH), υ6.65 (d, J: 8.2 Hz, 1H, PhH), 
υ5.1 (s, 2H, CH
2
), υ3.70 (s, 3H, OCH
3
) ppm.; HR-MS (EI+), 
m/z: 233.1041(M+, C
11
H
13
N
4
O
2
 for 233.1039).
N-(4-methoxyphenyl)-2-(1H-1,2,4-triazol-1-yl)acetamide 
(12)
Yield 33.4 %; mp: 167oC (water); IR (KBr) υ
max
 (cm-1): 
3269 (NH-st), 1683 (amide I), 1565 (amide II); 1H NMR 
(DMSO-d
6
) υ10.21 (brs, NH), υ8.51 (s, 1H, TrH), υ7.96 (d, 
J: 1.6 Hz, 1H, TrH), υ7.47 (d, J: 7.1 Hz, 2H, Ph2H), υ6.88 
(d, J: 7.1 Hz, 2H, Ph2H), υ5.07 (s, 2H, CH
2
), υ3.70 (d, J: 1.8 
Hz, 3H, OCH
3
) ppm.; HR-MS (EI+), m/z: 233.1044 (M+, 
C
11
H
13
N
4
O
2
 for 233.1039).
Biological activity
Acetylcholinesterase e.c.3.1.1.7., (Type Vı-S, from 
electric eel) and butyrylcholinesterase e.c. 3.1.1.8, from 
equine serum were purchased from Sigma–Aldrich 
(Steinheim, Germany). 5,5′-Dithiobis(2-nitrobenzoic acid) 
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(DTnB)-ellman’s reagent, buffer compounds (potassium 
dihydrogen phosphate, potassium hydroxide), sodium 
hydrogen carbonate, acetylthiocholine iodide (ATc) 
and butyrylthiocholine iodide (BTc) were obtained 
from Fluka (Buchs, Switzerland). Spectrophotometric 
measurements were performed on a Shimadzu uV/160-A 
Spectrophotometer.
Acetylcholinesterase/butyrylcholinesterase activity assay
enzyme activity was investigated using a slightly modified 
colorimetric method of ellman et al. (22, 23). Thiocholine, 
the product of the enzymatic hydrolysis, does not possess a 
significant chromophore in uV detection, therefore DTnB 
(ellman’s reagent) was used as a chromogenic reagent for the 
evaluation of enzyme activity. 
Stock solutions of the inhibitor compounds were prepared in 
2% DMSo, which were diluted with aqueous assay medium 
to a final content of organic solvent always lower than 0.2%. 
The enzyme activity was determined in the presence of at 
least five different concentrations of an inhibitor, generally 
between 10-3 and 10-8, in order to obtain the inhibition 
of Ache or Buche activity between 0% and 100%. each 
concentration was assayed in triplicate. Prior to use, all 
solutions were adjusted to 20°c. enzyme solution (2.5 units/
ml, 100 µl) and inhibitor solution (100 µl) were added into 
a cuvette containing the phosphate buffer (3.0 ml, 0.1 M; pH 
= 8.0). After 5 min of incubation, DTnB solution (0.01 M, 
100 µl) and ATc/BTc iodide (0.075 M, 20 µl) were added. 
After a rapid and immediate mixing, the absorption was 
measured at 412 nm (23). 
Molecular Docking Study
The crystal structure of Donepezil in complex with Ache 
were taken from the Protein Data Bank (pdb codes: 1eVe 
resolved at 2.5 Å). Heteroatoms and water molecules in the 
PDB file were removed and hydrogen atoms were added to 
the protein by using Moe 2014.09.1 (24). Prior to the docking 
calculations, an energy minimization using the AMBer99 
force field was performed on the enzyme. compound 11 
were built and protonated using the protonate 3D protocol 
and energy minimized using the MMFF94 force field in 
Moe 2014.09.1. Docking of the ligand was carried out using 
the GolD 5.2.1 program with default settings (25). A sphere 
of 20 Å around the carbonyl group of Glu199 was defined as 
the binding site for the ligand docking and 100 confirmations 
was allowed. The Goldscore standard precision (sp) were 
calculated and analyzed.
RESULTS AND DISCUSSION
Chemistry
ın this study, twelve 2-(1H-1,2,4-triazole-1yl)-N-
(substitutedphenyl)acetamide and 2-(1H-pyrazole-1yl)-N-
(substitutedphenyl)acetamide derivatives were synthesized 
to evaluate their cholinesterase inhibitory activity. For 
this purpose, appropriate anilines were reacted with 
2-chloroacetyl chloride to obtain the intermediates. Then 
they refluxed with pyrazole or 1,2,4-triazole to reach the 
final compounds. The structures of the title compounds were 
confirmed by ır, 1H-nMr and Hr-MS spectral analysis.
Among the synthesized compounds, compounds 3, 4, 5, 6, 
7 and 11 are listed in the literature with registry numbers 
cASrn 1171420-10-2, 1324900-89-1, 1324432-08-7, 
942863-57-2, 1457699-94-3, 1222962-44-8 respectively, but 
corresponding scientific reference data are not available. 
compounds 1 (21), 2 (21), 8 (26), 9 (27), 10 (26) and 12 (26) 
were reported previously. 
ın the ır spectra, carbonyl stretching band was recorded 
between 1708-1668 cm-1 and n-H stretching band was 
observed between 3324-3255 cm-1 supporting the presence of 
the amide structure for the title compounds (28, 29). 
The nMr data of the title compounds were recorded in cDcl3 
or DMSo-d6 solution and are in complete agreement with 
the expected resonance signals in terms of chemical shifts 
and integrations (28). ın the aliphatic region, the methylene 
protons were observed between δ 4.99-4.93 for pyrazole 
derivatives and δ 5.23-5.07 for 1,2,4-triazole derivatives. 
Thus, the proton signals of the methoxy substituents on 
phenyl ring were observed as expected between δ 4.01-3.70. 
ın the aromatic region, the proton signals of N-phenyl ring 
were recorded at expected chemical shifts with supporting 
splitting patterns. Also, the protons of the 5 membered rings 
were recorded with relevant splitting patterns and integration 
values. n-H protons were observed between δ 8.69-8.12 
for pyrazole derivatives and δ 10.56-9.93 for 1,2,4-triazole 
derivatives depending on the structure of the compound.
The structure and the purity of the title compounds was 
further verified by Hr-MS. The molecular ions of the 
compounds are in complete agreement with the calculated 
molecular weights and the purities are in the expected range. 
Cholinesterase Inhibitory Activity
ınhibitory potency of the final compounds against 
cholinesterase enzymes were evaluated by the spectroscopic 
method as described in the literature (22). The Ache/Buche 
inhibitory activity results are summarized as ıc50 values in 
Table 1.
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Table 1. In vitro cholinesterase activity of the title compounds 
compound Ache ıc50 ± SeM (μM)a Buche ıc50 ± SeM (μM)a
1 11.40 ± 0.61 > 100
2 11.85 ± 0.42 > 100
3 8.97 ± 0.25 > 100
4 8.32 ± 0.19 > 100
5 15.61 ± 0.32 > 100
6 13.18 ± 0.27 > 100
7 12.40 ± 0.32 > 100
8 15.39 ± 0.26 > 100
9 13.56 ± 0.23 > 100
10 7.41 ± 0.19 > 100
11 6.68 ± 0.21 > 100
12 8.14 ± 0.39 > 100
Galantha-
mine 0.43 ± 0.03 14.92 ± 0.57
a Data are means ± standard error of the mean of triplicate 
independent experiments. 
Generally, all of the synthesized compounds possessed 
moderate acetylcholinesterase inhibitory activity with 
different ratios. regarding compounds bearing chloride 
substituent, pyrazole derivatives have better Ache inhibitory 
activity than 1,2,4-triazole analogues. on the contrary, among 
the compounds bearing methoxy substituent, 1,2,4-triazole 
derivatives displayed better Ache inhibitory activity than 
their pyrazole analogues. Besides, activity evaluation of the 
1,2,4-triazole derivatives within themselves indicated that 
replacement of chloride substituent with methoxy group 
remarkably increased the Ache inhibitory activity.
Among the pyrazole derivatives, the most active compounds 
are compound 3 and 4 with ıc50 values 8.97 mM and 8.32 mM, 
respectively while in 1,2,4-triazole derivatives, compounds 10, 
11, 12 displayed the most inhibition against Ache with ıc50 
values 7.41 mM, 6.68 mM and 8.14 mM, respectively. compound 
11, namely 2-(1H-1,2,4-triazole-1yl)-N-(3-methoxyphenyl)
acetamide, was the most active compound in the series. 
According to Buche inhibitory activity results, none of the 
compounds displayed any inhibitory activity. Thus, we can 
easily point out that all of the title compounds are selective 
Ache inhibitors. 
Docking Studies
ın this study, molecular docking study was performed using 
GolD 5.2.1 to predict the interaction mode of compound 
11 for Ache. The X-ray crystal structure of the TcAche in 
complex with donepezil (PDB code 1eVe) was selected to 
build the starting model of Ache. compound 11 was chosen 
for molecular modeling as the most active compound in the 
series (Table 1).
As shown in Figure 1, compound 11 has two major binding 
interactions with TcAche. 1,2,4-triazole ring can interact 
with Phe330 residue and N-phenyl ring can interact 
with Tyr334 residue through π-π interactions. Phe330 is 
located in the hydrophobic pocket near the catalytic site of 
Ache (cAS) and it is known that several Ache inhibitors 
including tacrine have binding interactions with Phe330 
(30). on the other hand, Tyr334 is located in the peripheral 
site (PAS) of the enzyme and it can be proposed that 
compound 11 can interact with the PAS site of Ache. We 
have already mentioned that the narrow conformation of 
the Ache enzyme gorge leads small molecules like tacrine 
and donepezil to fit into the active site easily so it can be 
speculated that as our compounds are small molecules, they 
possessed Ache inhibitory activity. on the other hand, we 
can also speculate that our compounds didn’t display any 
Buche inhibitory activity due to the larger active site gorge 
of Buche in respect to Ache (18, 30). 
Bir grup fenilasetamit türevi bileşiklerin sentezi ve 
kolinesteraz inhibitör aktivite çalışmaları
ÖZET
Pirazol veya 1,2,4-triazol taşıyan bir grup N-fenilasetamit 
türevi sentezlenmiş ve kolinesteraz inhibitör aktiviteleri 
test edilmiştir. Asetilkolinesteraz ve bütirilkolinesteraz 
inhibitör aktiviteleri ellman’ın spektroskobik metoduna 
göre test edilmiştir. elde edilen sonuçlar, tüm bileşiklerin 
orta derecede ve seçici asetilkolinesteraz inhibitör aktivite 
gösterdiğini ortaya koymuştur. Serideki en aktif bileşik 
6.68 mM’lık ıc50 değeriyle 2-(1H-1,2,4-triazol-1-il)-N-(3-
metoksifenil)asetamit olup bu bileşiğe doking çalışmaları 
da yapılmıştır.
Anahtar kelimeler: Alzheimer hastalığı, pirazol, 1,2,4-triazol, 
asetamit, kolinesteraz inhibitör aktivite
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Figure 1. Binding mode of compound 11 inside TcAche. 
compound 11 is represented as green stick; the most 
involved residues are named and represented as brown sticks 
for the TcAche. 
ın conclusion, the preliminary activity screening results 
have demonstrated that N-phenylacetamide template 
bearing pyrazole and 1,2,4-triazole rings have selective 
acetylcholinesterase inhibitory activity and preliminary 
molecular modeling studies proposed a binding interaction 
between the most active compound and the PAS region of 
Ache. These findings can be assumed as the beginning for 
further studies to design more effective acetylcholinesterase 
inhibitors binding both PAS and cAS sites of the Ache 
enzyme.
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